Jaguar Health Inc
NASDAQ:JAGX

Watchlist Manager
Jaguar Health Inc Logo
Jaguar Health Inc
NASDAQ:JAGX
Watchlist
Price: 0.9975 USD 7.26% Market Closed
Market Cap: 3.5m USD

Operating Margin
Jaguar Health Inc

-294%
Current
-301%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-294%
=
Operating Profit
-34.6m
/
Revenue
11.8m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Jaguar Health Inc
NASDAQ:JAGX
3.7m USD
-294%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
498.9B USD
27%
CH
Roche Holding AG
SIX:ROG
261.4B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
24%
CH
Novartis AG
SIX:NOVN
210.3B CHF
33%
US
Merck & Co Inc
NYSE:MRK
264.8B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
143.2B USD
29%
No Stocks Found

Jaguar Health Inc
Glance View

Market Cap
3.7m USD
Industry
Pharmaceuticals

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 52 full-time employees. The company went IPO on 2015-05-13. The firm is focused on developing plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with gastrointestinal (GI) distress, including chronic and debilitating diarrhea. The firm operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. Its Canalevia-CA1 is used for chemotherapy-induced diarrhea in dogs. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. Its wholly owned subsidiary is Napo Pharmaceuticals, Inc.

JAGX Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-294%
=
Operating Profit
-34.6m
/
Revenue
11.8m
What is the Operating Margin of Jaguar Health Inc?

Based on Jaguar Health Inc's most recent financial statements, the company has Operating Margin of -294%.

Back to Top